BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37812652)

  • 1. Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.
    Mooney B; Negri GL; Shyp T; Delaidelli A; Zhang HF; Spencer Miko SE; Weiner AK; Radaoui AB; Shraim R; Lizardo MM; Hughes CS; Li A; El-Naggar AM; Rouleau M; Li W; Dimitrov DS; Kurmasheva RT; Houghton PJ; Diskin SJ; Maris JM; Morin GB; Sorensen PH
    Clin Cancer Res; 2024 Mar; 30(5):1022-1037. PubMed ID: 37812652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.
    Town J; Pais H; Harrison S; Stead LF; Bataille C; Bunjobpol W; Zhang J; Rabbitts TH
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3603-8. PubMed ID: 26979953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.
    Grunewald TG; Diebold I; Esposito I; Plehm S; Hauer K; Thiel U; da Silva-Buttkus P; Neff F; Unland R; Müller-Tidow C; Zobywalski C; Lohrig K; Lewandrowski U; Sickmann A; Prazeres da Costa O; Görlach A; Cossarizza A; Butt E; Richter GH; Burdach S
    Mol Cancer Res; 2012 Jan; 10(1):52-65. PubMed ID: 22080479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.
    Potratz J; Tillmanns A; Berning P; Korsching E; Schaefer C; Lechtape B; Schleithoff C; Unland R; Schäfer KL; Müller-Tidow C; Jürgens H; Dirksen U
    Mol Oncol; 2016 May; 10(5):677-92. PubMed ID: 26739507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma.
    Zhang HF; Hughes CS; Li W; He JZ; Surdez D; El-Naggar AM; Cheng H; Prudova A; Delaidelli A; Negri GL; Li X; Ørum-Madsen MS; Lizardo MM; Oo HZ; Colborne S; Shyp T; Scopim-Ribeiro R; Hammond CA; Dhez AC; Langman S; Lim JKM; Kung SHY; Li A; Steino A; Daugaard M; Parker SJ; Geltink RIK; Orentas RJ; Xu LY; Morin GB; Delattre O; Dimitrov DS; Sorensen PH
    Cancer Discov; 2021 Nov; 11(11):2884-2903. PubMed ID: 34021002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Hope on the Surface of Ewing Sarcoma.
    Bailey KM
    Clin Cancer Res; 2024 Mar; 30(5):934-936. PubMed ID: 38113033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
    Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
    Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Functional genomics of Ewing sarcoma].
    Grünewald TGP
    Pathologe; 2017 Nov; 38(Suppl 2):198-201. PubMed ID: 28849372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in Ewing sarcoma: a translational point of view.
    Gargallo P; Juan A; Yáñez Y; Dolz S; Segura V; Castel V; Cañete A
    Clin Transl Oncol; 2020 Sep; 22(9):1440-1454. PubMed ID: 32026343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma.
    Lynn M; Wang Y; Slater J; Shah N; Conroy J; Ennis S; Morris T; Betts DR; Fletcher JA; O'Sullivan MJ
    Diagn Mol Pathol; 2013 Jun; 22(2):76-84. PubMed ID: 23628818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
    Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
    Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immunotherapy strategies for Ewing sarcoma.
    Rossig C
    Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ewing Sarcoma, an Update on Molecular Pathology with Therapeutic Implications.
    de Alava E
    Surg Pathol Clin; 2017 Sep; 10(3):575-585. PubMed ID: 28797503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Round Blue Cell Sarcoma Other Than Ewing Sarcoma: What Should an Oncologist Know?
    Davis JL; Rudzinski ER
    Curr Treat Options Oncol; 2020 Sep; 21(11):90. PubMed ID: 32875423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCOR-CCNB3 (Ewing-like) sarcoma: a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma.
    Puls F; Niblett A; Marland G; Gaston CL; Douis H; Mangham DC; Sumathi VP; Kindblom LG
    Am J Surg Pathol; 2014 Oct; 38(10):1307-18. PubMed ID: 24805859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.
    Roundhill EA; Chicon-Bosch M; Jeys L; Parry M; Rankin KS; Droop A; Burchill SA
    Cell Oncol (Dordr); 2021 Oct; 44(5):1065-1085. PubMed ID: 34403115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular assessment of circulating exosomes toward liquid biopsy diagnosis of Ewing sarcoma family of tumors.
    Zhang P; Samuel G; Crow J; Godwin AK; Zeng Y
    Transl Res; 2018 Nov; 201():136-153. PubMed ID: 30031766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.
    Cohen IJ; Toledano H; Stein J; Kollender Y; Fenig E; Konen O; Bar-Sever Z; Issakov J; Feinmesser M; Avigad S; Ash S
    Cancer Chemother Pharmacol; 2019 May; 83(5):859-866. PubMed ID: 30770960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and oncologic outcomes of patients with Ewing sarcoma of the scapula.
    Yeung CM; Kaiser CL; Peleteiro-Pensado M; Barrientos-Ruiz I; Ortiz-Cruz EJ; Anderson ME; Raskin KA; Lozano-Calderón SA
    Surg Oncol; 2021 Sep; 38():101619. PubMed ID: 34157657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.